These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 36934366)

  • 21. Continuous intrathecal orexin delivery inhibits cataplexy in a murine model of narcolepsy.
    Kaushik MK; Aritake K; Imanishi A; Kanbayashi T; Ichikawa T; Shimizu T; Urade Y; Yanagisawa M
    Proc Natl Acad Sci U S A; 2018 Jun; 115(23):6046-6051. PubMed ID: 29784823
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Safety of Daridorexant in Older and Younger Adults with Insomnia Disorder: A Secondary Analysis of a Randomised Placebo-Controlled Trial.
    Fietze I; Bassetti CLA; Mayleben DW; Pain S; Seboek Kinter D; McCall WV
    Drugs Aging; 2022 Oct; 39(10):795-810. PubMed ID: 36098936
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. US Modafinil in Narcolepsy Multicenter Study Group.
    Ann Neurol; 1998 Jan; 43(1):88-97. PubMed ID: 9450772
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The orexin receptor 2 (OX2R)-selective agonist TAK-994 increases wakefulness without affecting cerebrospinal fluid orexin levels in cynomolgus monkeys.
    Yamada R; Narita N; Ishikawa T; Kakehi M; Kimura H
    Pharmacol Biochem Behav; 2024 Jan; 234():173690. PubMed ID: 38061670
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Solriamfetol for the Treatment of Excessive Daytime Sleepiness in Participants with Narcolepsy with and without Cataplexy: Subgroup Analysis of Efficacy and Safety Data by Cataplexy Status in a Randomized Controlled Trial.
    Dauvilliers Y; Shapiro C; Mayer G; Lammers GJ; Emsellem H; Plazzi G; Chen D; Carter LP; Lee L; Black J; Thorpy MJ
    CNS Drugs; 2020 Jul; 34(7):773-784. PubMed ID: 32588401
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Face validation and pharmacologic analysis of Sik3
    Elhosainy A; Suzuki-Abe H; Kaushik MK; Kim SJ; Saitoh T; Ishikawa Y; Hotta-Hirashima N; Miyoshi C; Funato H; Yanagisawa M
    Eur J Pharmacol; 2023 Sep; 954():175877. PubMed ID: 37356786
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Approved and investigational uses of modafinil : an evidence-based review.
    Kumar R
    Drugs; 2008; 68(13):1803-39. PubMed ID: 18729534
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy.
    Harsh JR; Hayduk R; Rosenberg R; Wesnes KA; Walsh JK; Arora S; Niebler GE; Roth T
    Curr Med Res Opin; 2006 Apr; 22(4):761-74. PubMed ID: 16684437
    [TBL] [Abstract][Full Text] [Related]  

  • 29. OX2R-selective orexin agonism is sufficient to ameliorate cataplexy and sleep/wake fragmentation without inducing drug-seeking behavior in mouse model of narcolepsy.
    Yamamoto H; Nagumo Y; Ishikawa Y; Irukayama-Tomobe Y; Namekawa Y; Nemoto T; Tanaka H; Takahashi G; Tokuda A; Saitoh T; Nagase H; Funato H; Yanagisawa M
    PLoS One; 2022; 17(7):e0271901. PubMed ID: 35867683
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial.
    Dauvilliers Y; Bassetti C; Lammers GJ; Arnulf I; Mayer G; Rodenbeck A; Lehert P; Ding CL; Lecomte JM; Schwartz JC;
    Lancet Neurol; 2013 Nov; 12(11):1068-75. PubMed ID: 24107292
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modafinil for treatment of residual excessive sleepiness in nasal continuous positive airway pressure-treated obstructive sleep apnea/hypopnea syndrome.
    Black JE; Hirshkowitz M
    Sleep; 2005 Apr; 28(4):464-71. PubMed ID: 16171291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dosing regimen effects of modafinil for improving daytime wakefulness in patients with narcolepsy.
    Schwartz JR; Feldman NT; Bogan RK; Nelson MT; Hughes RJ
    Clin Neuropharmacol; 2003; 26(5):252-7. PubMed ID: 14520165
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized study of solriamfetol for excessive sleepiness in narcolepsy.
    Thorpy MJ; Shapiro C; Mayer G; Corser BC; Emsellem H; Plazzi G; Chen D; Carter LP; Wang H; Lu Y; Black J; Dauvilliers Y
    Ann Neurol; 2019 Mar; 85(3):359-370. PubMed ID: 30694576
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of sodium oxybate, modafinil, and combination treatment on excessive daytime sleepiness in patients who have narcolepsy with or without cataplexy.
    Black J; Swick T; Bogan R; Lai C; Carter LP
    Sleep Med; 2016 Aug; 24():57-62. PubMed ID: 27810187
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The roles of orexins in sleep/wake regulation.
    Mieda M
    Neurosci Res; 2017 May; 118():56-65. PubMed ID: 28526554
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of intranasal orexin-A (hypocretin-1) on sleep, wakefulness and attention in narcolepsy with cataplexy.
    Weinhold SL; Seeck-Hirschner M; Nowak A; Hallschmid M; Göder R; Baier PC
    Behav Brain Res; 2014 Apr; 262():8-13. PubMed ID: 24406723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Maintenance of wakefulness with lisdexamfetamine dimesylate, compared with placebo and armodafinil in healthy adult males undergoing acute sleep loss.
    Gasior M; Freeman J; Zammit G; Donnelly P; Gao J; Ferreira-Cornwell MC; Roth T
    J Clin Psychopharmacol; 2014 Dec; 34(6):690-6. PubMed ID: 25159886
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparing Treatment Effect Measurements in Narcolepsy: The Sustained Attention to Response Task, Epworth Sleepiness Scale and Maintenance of Wakefulness Test.
    van der Heide A; van Schie MK; Lammers GJ; Dauvilliers Y; Arnulf I; Mayer G; Bassetti CL; Ding CL; Lehert P; van Dijk JG
    Sleep; 2015 Jul; 38(7):1051-8. PubMed ID: 25902810
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Narcolepsy in the older adult: epidemiology, diagnosis and management.
    Chakravorty SS; Rye DB
    Drugs Aging; 2003; 20(5):361-76. PubMed ID: 12696996
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Wake-promoting effects of ONO-4127Na, a prostaglandin DP1 receptor antagonist, in hypocretin/orexin deficient narcoleptic mice.
    Sagawa Y; Sato M; Sakai N; Chikahisa S; Chiba S; Maruyama T; Yamamoto J; Nishino S
    Neuropharmacology; 2016 Nov; 110(Pt A):268-276. PubMed ID: 27474349
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.